Background: An elevated prevalence of Type 2 diabetes (T2D) has been observed in people with psychotic disorders and their relatives compared to the general population. It is not known whether this population also has increased genetic risk for T2D. Methods: Subjects included probands with schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder, their first-degree relatives without psychotic disorders, and healthy controls, who participated in the Bipolar Schizophrenia Network for Intermediate Phenotypes study. We constructed sets of polygenic risk scores for T2D (PGRS T2D ) and schizophrenia (PGRS SCHIZ ) using publicly available data from genome-wide association studies. We then explored the correlation of PGRS T2D with psychiatric proband or relative status, and with self-reported diabetes. Caucasians and AfricaneAmericans were analyzed separately. We also evaluated correlations between PGRS SCHIZ and diabetes mellitus among Caucasian probands and their relatives. Results: In Caucasians, PGRS T2D was correlated with self-reported diabetes mellitus within probands, but was not correlated with proband or relative status in the whole sample. In AfricaneAmericans, a PGRS T2D based on selected risk alleles for T2D in this population did not correlate with proband or relative status. PGRS SCHIZ was not correlated with self-reported diabetes within Caucasian probands. Conclusion: Differences in polygenic risk for T2D do not explain the increased prevalence of diabetes mellitus observed in psychosis probands and their relatives.
Introduction
An elevated prevalence of diabetes mellitus among individuals with psychosis has been noted long before the invention of atypical antipsychotic medication. In The Pathology of Mind, published in 1897, Sir Henry Maudsley observed that "diabetes often shows itself in families in which insanity prevails". In 1991, before common use of atypical antipsychotics, the Schizophrenia Patient Outcomes Research Team (PORT) found that the rate of diabetes mellitus among people with schizophrenia was 15%, exceeding the general population (Dixon et al., 2000) . In the post-antipsychotic era, the prevalence of Type 2 diabetes mellitus (T2D) is reportedly in the range of 11e15% in individuals with schizophrenia and is around 12% in those with bipolar disorder (Regenold et al., 2002; Ruzickova et al., 2003) .
Many possible reasons have been proposed for this elevated prevalence, including lifestyle choices, poor compliance with or access to medical care, and most notably, the effects of antipsychotic medication. However, an increased genetic risk of T2D among those with schizophrenia or bipolar disorder is an underexplored possibility (Holt and Mitchell, 2015) . Studies of antipsychotic naïve individuals with schizophrenia have observed elevated plasma insulin levels (Chen et al., 2013; Ryan et al., 2003; Venkatasubramanian et al., 2007) , lower insulin growth factor (IGF-1) levels (Venkatasubramanian et al., 2007) , impaired glucose tolerance (Fernandez-Egea et al., 2008; Spelman et al., 2007) and elevated fasting glucose, even when health habits are accounted for (Kirkpatrick et al., 2012; Ryan et al., 2003) . However, other studies have not confirmed these findings (Sengupta et al., 2008) . In addition, some studies have noted increased rates of T2D among relatives of people with schizophrenia (Fernandez-Egea et al., 2008; Mothi et al., 2015; Mukherjee et al., 1989) , and a clustering of diabetes mellitus and psychosis in family histories of people with psychosis (Foley et al., 2015) . These family data raise the possibility of shared genetic and environmental risk factors between T2D and psychosis.
Some studies have explicitly explored whether specific genes are shared between these two disorders. Several association studies have reported significant correlations between schizophrenia and well-replicated candidate genes for T2D, including ARHGEF11 (Mizuki et al., 2014) , IGF2BP2 (Zhang et al., 2013) , and TCF7L2 (Hansen et al., 2011; Irvin et al., 2009) , among others (Lin and Shuldiner, 2010) . In a cross-disorder analysis, Stringer et al. (2014) found that a polygenic risk score for schizophrenia was correlated with T2D in a case-control sample of individuals with and without T2D (Stringer et al., 2014) . However, no study has examined whether polygenic risk for T2D is associated with psychosis. Also, while several studies have reported increased prevalence of diabetes mellitus among relatives of people with psychosis, it is not known whether increased genetic risk for T2D accounts for this finding.
The primary aim of this study was to evaluate whether polygenic loading for T2D correlates with psychotic disorder proband status, or with first-degree relative status. Our additional goals were to determine (1) whether polygenic loading for T2D correlates with self-reported diabetes mellitus among probands and their relatives; and (2) whether polygenic loading for schizophrenia correlates with diabetes mellitus among probands or their relatives.
Materials and methods

Study design and measures
Analysis was conducted on data from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP) study, a multi-site investigation of psychosis biomarkers. This investigation was approved by the Institutional Review Boards for each site and was conducted in accordance with the Declaration of Helsinki. Subjects included individuals with schizophrenia, schizoaffective disorder, or bipolar I with psychosis, their first-degree relatives, and healthy controls. Relatives with Axis I or II psychotic disorders (e.g. schizoid, schizotypal, or paranoid personality disorders), or who reported taking antipsychotics, were excluded so that the remaining sample consisted of subjects with familial risk of psychosis but without the experience of having a chronic psychotic disorder. Demographic data are presented in Table 1 . The Structured Clinical Interview for DSM-IV (First et al., 2002) was performed on all subjects and diagnosis was determined using a consensus process, led by a senior clinician, which involved review of the structured diagnostic interview, medical and psychiatric records. Subjects were asked to self-report current co-morbid medical diagnoses, including any type of diabetes mellitus. The data collection process did not distinguish between Type 1 and Type 2 diabetes mellitus. Subjects also reported whether or not they were taking medication to treat diabetes. Those who either reported a diagnosis of diabetes or being on medication to treat diabetes were classified as having diabetes mellitus.
Collection and quality control of genetic data
Genomic data were collected using the Illumina Infinium PsychArray BeadChip™ platform. Genotype calling was performed at the Broad Institute using methods detailed online (Broad Institute, 2015) , and genotypes underwent quality control using PLINK 1.9 (Chang et al., 2015; Purcell et al., 2007) , based on a standardized protocol (Anderson et al., 2010) . Details have been described in earlier work (Meda et al., 2014; Narayanan et al., 2015) . To summarize, markers were removed if they had a missing rate greater than 5%, deviated from HardyeWeinberg equilibrium (p < 0.000001), had a very low minor allele frequency (<0.01), or demonstrated a significantly different call rate between psychiatric probands and controls (p < 0.00001). Subjects were removed for discordant sex information, outlying heterozygosity (>3 standard deviations above the mean), or excessive proportion of missing genotype data (>0.05).
Imputation
Imputation of genetic data was performed using ShapeIt for prephasing (Delaneau et al., 2012 (Delaneau et al., , 2013 Howie et al., 2012) and Impute2 for imputation (Howie et al., 2009 (Howie et al., , 2012 , using the multiethnic 1000 Genomes phase 3 data as a reference panel (Howie et al., 2011 ). Chromosomes were phased, then divided into 5 million base pair chunks for imputation. Imputed SNPs were removed for poor quality (information score less than 0.5) (Marchini and Howie, 2010) or a minor allele frequency < 0.01. For polygenic risk score analyses, linkage disequilibrium pruning was performed in PLINK 1.9 based on a pairwise R 2 of 0.5 and a window of 50 SNPs, shifting 5 SNPs at a time. 390 SNPs that approached genome-wide significance (p-value under 5 Â 10 À6 ) in a multiethnic T2D study (DIAbetes Genetics Replication Meta-analysis Consortium et al., 2014) were also retained.
Population stratification and treatment of ethnicity effects
Principal component analysis was performed in the preimputed whole sample (Caucasians and AfricaneAmericans) using the "dpca" function in PLINK 1.9, and the first five components were retained as covariates to control for population stratification in subsequent analyses.
Due to potential confounding effects of race, Caucasians and AfricaneAmerican were subsequently analyzed separately. This decision was made because the odds ratios used to construct polygenic risk scores for schizophrenia (PGRS SCHIZ ) and diabetes (PGRS T2D ) originated from meta-analyses of genome-wide association studies that did not include African populations (DIAbetes Genetics Replication Meta-analysis Consortium et al., 2014; Morris et al., 2012 ; Schizophrenia Working Group of the Psychiatric Genomics, 2014), and thus the accuracy of these odds ratios is unclear in populations of African descent. Whole-genome odds ratios are not publicly available for AfricaneAmericans, but some work indicates that the directionality of effect of at least some T2D risk alleles is similar across populations . As exploratory analyses, we constructed unweighted PGRS T2D (using the same markers but weighting risk alleles equally) for AfricaneAmericans using markers studied in non-African populations (DIAbetes Genetics Replication Meta-analysis Consortium et al., 2014) . In addition, as described below, we used published data on selected T2D risk alleles from a meta-analysis of AfricaneAmerican samples (Ng et al., 2014) to construct an additional weighted PGRS T2D specific for AfricaneAmericans, though this score only included a small number of markers.
Construction of PGRS
For Caucasians, a first set of polygenic risk scores for T2D (PGRS T2D ) was constructed using odds ratio data from a metaanalysis of T2D genome-wide association studies performed largely in Caucasians (Morris et al., 2012) . This set of PGRS T2D consisted of scores constructed at 500-SNP increments using the following process: SNPs were ordered from lowest to highest p value according to their association with T2D in the meta-analysis. The first PGRS T2D was comprised of the top 500 SNPs most associated with T2D (in the meta-analysis) that were also available in our imputed sample, the second PGRS T2D was comprised of the top 1000 SNPs, and each subsequent PGRS T2D was formed by incorporating an additional 500 SNPs in the PGRS. Polygenic risk scores were constructed with the "score" function in PLINK 1.9. This function multiplies the log of the odds ratio for a risk allele (per meta-analytic data) by the number of risk alleles carried by that individual subject (either 0, 1, or 2), performs and sums this across all SNPs, and divides by the total number of SNPs to generate a polygenic risk score (Purcell et al., 2009) .
A second set of PGRS T2D for the Caucasian sample was constructed using a similar process, with odds ratio data from a transethnic meta-analysis of Caucasians, East Asians, Mexicans, and South Asians (DIAbetes Genetics Replication Meta-analysis Consortium et al., 2014) . A similar process was used to calculate a set of PGRS SCHIZ for Caucasians at increments of 500 SNPs, using PGC2 Consortium data (Schizophrenia Working Group of the Psychiatric Genomics, 2014). For construction of unweighted PGRS T2D in AfricaneAmericans, risk alleles (with odds ratio > 1 for association with T2D per trans-ethnic meta-analytic data) were weighted equally (DIAbetes Genetics Replication Meta-analysis Consortium et al., 2014).
Statistical analyses 2.6.1. Analyses with PGRS T2D
In Caucasians, two sets of PGRS T2D were analyzed, using Caucasian meta-analysis data (Morris et al., 2012) , and trans-ethnic meta-analysis data (DIAbetes Genetics Replication Meta-analysis Consortium et al., 2014) . In AfricaneAmericans, unweighted scores were analyzed (DIAbetes Genetics Replication Meta-analysis Consortium et al., 2014) .
We considered PGRS T2D-DIAB-PRO , PGRS T2D-DIAB-REL , and PGRS T2D-DIAB-PRO/REL to quantify polygenic risk for T2D that are maximally associated with self-reported diabetes status within probands, within relatives, and within probands and relatives combined, respectively. We considered PGRS T2D-PRO , PGRS T2D-REL , and PGRS T2D-PRO/REL to quantify polygenic risk for T2D that are maximally associated with proband status, relative status, or proband/ relative status (i.e., being either a proband or relative), respectively. To identify PGRS T2D-DIAB-PRO , each PGRS T2D was correlated with selfreported diabetes mellitus among probands, with age, sex, and scores on the first five principal components as covariates in a logistic regression model. The PGRS T2D with the highest Nagelkerke R 2 for its associated model was selected and reported as the PGRS T2D-DIAB-PRO . This analysis was repeated within relatives alone to identify PGRS T2D-DIAB-REL , and within relatives and probands combined to identify PGRS T2D-DIAB-PRO/REL . Next, to identify PGRS T2D-PRO , each PGRS T2D was correlated with psychiatric proband versus control status using logistic regression, with covariates of age, sex, and five principal components of population stratification. The PGRS T2D with the highest Nagelkerke R 2 for its associated model was selected and reported as the PGRS T2D-PRO . This analysis was repeated with relatives and controls to identify PGRS T2D-REL , and with probands, relatives, and controls to identify PGRS T2D-PRO/REL .
Finally, as an exploratory analysis, the selected PGRS T2D-DIAB-PRO and PGRS T2D-PRO were assessed for correlations with self-reported diabetes or proband status, within each proband diagnostic group (i.e., schizophrenia, schizoaffective, and bipolar disorder), for each race.
Analysis with PGRS SCHIZ in Caucasians
We considered PGRS SCHIZ-DIAB-PRO , PGRS SCHIZ-DIAB-REL , and PGRS SCHIZ-DIAB-PRO/REL to quantify the polygenic risk for schizophrenia that is maximally associated with self-reported diabetes mellitus among probands, relatives, and probands and relatives together, respectively. Because use of antipsychotic medication may confound this association, antipsychotic medication status was first correlated with self-reported diabetes mellitus status in probands via logistic regression. Antipsychotic medication status was a binary variable representing whether or not the subject was taking antipsychotics at time of evaluation. Each PGRS SCHIZ was correlated with diabetes mellitus status among probands to identify PGRS SCHIZ-DIAB-PRO , with covariates of age, sex, five principal components, and antipsychotic medication status. This analysis was repeated in relatives alone and probands and relatives together to identify PGRS SCHIZ-DIAB-REL and PGRS SCHIZ-DIAB-PRO/REL , respectively.
Post-hoc analyses within AfricaneAmericans
We performed an association analysis within our AfricaneAmerican sample using 68 risk alleles from a meta-analysis of association studies of T2D in AfricaneAmericans (Ng et al., 2014) . These risk alleles had been significant at p ¼ 1 Â 10 À5 at Stage 1 of this meta-analysis, or they had been selected a priori from the literature for replication (Tables S4 and S5 from the cited study). The logistic regression function in PLINK 1.9 was used to correlate the risk alleles with proband/relative status, then with selfreported diabetes, with covariates of age, sex, and five principal components of population stratification, using an additive model. Proband/relative status was a covariate in the association with selfreported diabetes, and self-reported diabetes was a covariate in the association with proband/relative status. Next, we created a polygenic risk score from 62 of these 68 selected SNPs, using odds ratios from the Ng et al. meta-analysis, and correlated this score with control versus proband/relative status, and with self-reported diabetes. Finally, to assess for ancestry differences between AfricaneAmerican probands, relatives, and controls, the five principal components of population stratification were correlated with control versus proband/relative status using logistic regression.
Analyses with antipsychotic medication status
Antipsychotic medication status (defined earlier as a binary variable) was evaluated for correlation with self-reported diabetes mellitus among probands using a regression model and covariates of age, sex, and the five principal components of population stratification. This analysis was repeated instead using current antipsychotic dose in chlorpromazine equivalents (CPZ dose), which was available for some psychiatric probands (N ¼ 247 in Caucasians, N ¼ 165 in AfricaneAmericans).
Results
Demographics
Within each race, prevalence of self-reported diabetes mellitus was significantly different across healthy controls, probands, and relatives, with probands demonstrating the highest prevalence (Table 1, Fig. 1 ). Prevalence of diabetes did not differ between AfricaneAmerican and Caucasian controls, but was higher in AfricaneAmerican probands and relatives than in Caucasian probands and relatives.
Analyses with PGRS T2D
Among Caucasians, PGRS T2D-DIAB-PRO and PGRS T2D-DIAB-PRO/REL were correlated with self-reported diabetes status whether constructed with Caucasian-only meta-analysis data or trans-ethnic meta-analysis data. Among Caucasian relatives, PGRS T2D-DIAB-REL did not correlate with self-reported diabetes mellitus (Table 2, Supplementary Fig. 1 ). PGRS T2D-PRO , PGRS T2D-REL , and PGRS T2D-PRO/ REL were not significantly correlated with psychiatric proband, relative, or proband/relative status (Table 2) .
Among AfricaneAmericans, PGRS T2D-DIAB-REL was significantly correlated with self-reported diabetes within relatives (Table 3 , Supplementary Fig. 2 ). PGRS T2D-PRO , PGRS T2D-REL , and PGRS T2D-PRO/ REL were correlated with proband, relative, and proband/relative status, respectively (Table 3) .
Within diagnostic categories, several correlations remained significant, though these would not have survived correction for multiple comparisons (Supplementary Table 1 ).
Analyses with PGRS SCHIZ in Caucasians
PGRS SCHIZ score was not correlated with diabetes mellitus in probands or relatives (Table 2) .
Post-hoc analyses within AfricaneAmericans
Three out of 68 alleles were nominally associated with proband/ relative status, and eight alleles were associated with self-reported diabetes mellitus, but these results did not survive multiple comparison correction (Supplementary Table 2 ). A weighted polygenic risk score constructed from 62 SNPs was not significantly correlated with either self-reported diabetes or proband/relative status. One of five principal components of population stratification was associated with proband/relative status (p ¼ 0.04).
Analyses with antipsychotic medication
Antipsychotic medication status and CPZ dose did not correlate with diabetes mellitus among probands in either race.
Discussion
In this study, we found an elevated prevalence of selfreported diabetes in probands with psychotic disorders and their relatives compared to controls, in concordance with Fig. 1 . Prevalence of self-reported diabetes mellitus by race and diagnostic group. Prevalence is depicted as a percentage in our sample. HC ¼ healthy controls. SZP, SADP, and BPP ¼ probands with schizophrenia, schizoaffective disorder, and psychotic bipolar disorder, respectively. SZR, SADR, and BPR ¼ relatives of probands with schizophrenia, schizoaffective disorder, and bipolar disorder, respectively. previously published data (Bushe and Holt, 2004; Dixon et al., 2000; Fernandez-Egea et al., 2008; Mothi et al., 2015; Mukherjee et al., 1989) . Prevalence of self-reported diabetes was also elevated in AfricaneAmerican probands in comparison with Caucasian probands, corroborating findings in the general population, in which incidence (Brancati et al., 2000) and prevalence of T2D (Carter et al., 1996) are also higher in AfricaneAmericans. Modifiable risk factors such as adiposity (body-mass index and waist-hip ratio) partly, but not fully, explain increased risk for development of T2D in AfricaneAmericans (Brancati et al., 2000; Marshall, 2005) . Socioeconomic status also does not fully account for this increased prevalence (Robbins et al., 2000) ; liability to some aspects of T2D pathophysiology, such as insulin resistance, may differ as well (Marshall, 2005) . Finally, genetic liability for T2D may be increased among those of African descent (Cheng et al., 2012) .
Polygenic analyses in our sample did not demonstrate an association of polygenic risk scores for T2D with psychosis proband or relative status among Caucasians. One interpretation of the findings is that among Caucasians with chronic psychotic disorders, lifestyle risk factors and antipsychotic medication use primarily account for their higher prevalence of diabetes, rather than any difference in genetic liability. These lifestyle factors include diminished physical activity, poor diet, and smoking (Bly et al., 2014) . Antipsychotic medication is associated with T2D (CrossDisorder Group of the Psychiatric Genomics et al., 2013; Nielsen et al., 2010) perhaps because of the effect of these medications on weight gain (Bak et al., 2014) , insulin release (Teff et al., 2013) , glucose transport (Dwyer et al., 1999) , and muscarinic receptor signaling (Weston-Green et al., 2012) . Additionally, prolonged stress and autonomic activity may contribute to findings of glucose dysregulation among antipsychotic-naïve individuals with psychosis (Shiloah et al., 2003) . The higher prevalence of diabetes in relatives may potentially reflect environmental risk factors shared with probands, such as poor diet and physical inactivity. In addition, relatives of people with psychotic disorders have a higher prevalence of non-psychotic mental illness compared to the general population (Maier et al., 1994) , such as depression, and these disorders have themselves been associated with T2D (Roy and Lloyd, 2012) .
In the AfricaneAmerican sample, an unweighted PGRS T2D was associated with proband status. However, even after co-varying for population stratification, subtle ancestry differences between the AfricaneAmerican probands and AfricaneAmerican controls remain a likely explanation of this finding, given that one of five principal components of population stratification was significantly associated with proband/relative status among AfricaneAmericans. An unweighted PGRS T2D-DIAB was correlated significantly but weakly with self-reported diabetes in AfricaneAmerican relatives, but not in probands. Thus, the validity of these scores in AfricaneAmericans is unclear. A weighted PGRS T2D using a small number of markers did not significantly correlate with proband/ relative status. These findings suggest that, as with Caucasians, polygenic loading for T2D does not account for the higher prevalence of diabetes among AfricaneAmerican probands compared to controls.
PGRS SCHIZ was not correlated with self-reported diabetes mellitus among Caucasian probands or relatives. This finding corroborates two other studies that correlated PGRS SCHIZ with T2D in case/control samples of T2D and found either no correlation (Purcell et al., 2009) , or a small correlation (Stringer et al., 2014) . We found no correlation of current antipsychotic medication use or dosage with diabetes, in contrast to the substantial evidence in the literature for such a correlation (Sernyak et al., 2002; Smith et al., 2008) , which suggests that the crosssectional medication data in our sample was not an adequate proxy for longitudinal antipsychotic exposure.
Of potential clinical interest is the strong correlation between self-reported diabetes and PGRS T2D among Caucasian probands. While this correlation was expected, it raises the question of whether PGRS T2D may have value in predicting the development of T2D and other metabolic co-morbidities in this population. Vassy et al. recently reported that PGRS T2D was significantly correlated with incident T2D in the general population, but did not add value to existing clinical and demographic predictive models (Vassy et al., 2014) . However, this study also found that PGRS T2D had greater predictive value among younger individuals without overt clinical risk factors. Young individuals with psychotic disorders are particularly vulnerable to development of T2D due to environmental and iatrogenic risk factors but may lack traditional laboratory predictors of T2D; thus, PGRS T2D may have greater predictive value in this population. The precise relation between PGRS T2D and diabetes risk could not be evaluated in this study, but deserves further investigation.
There are a number of limitations with this study. One significant limitation was that the diagnosis of diabetes status was determined by self-report rather than laboratory measures; however, this limitation did not affect our primary research question, which was to examine whether polygenic loading for T2D is associated with psychotic disorder proband or relative status. Additionally, we found that PGRS T2D was significantly correlated with self-reported diabetes, supporting reasonable validity of this measure. Studies indicate that self-reported medical histories, including histories of T2D, can be reasonably accurate (Pastorino et al., 2014; Selim et al., 2004) . A second limitation was that these self-reported data did not distinguish between Type 1 and Type 2 diabetes mellitus, which have significantly different etiologies, demographic and clinical features. While this does not affect our primary research aim, the correlation between PGRS T2D and self-reported diabetes may have been diluted if some of these individuals actually had T1D. However, only an estimated 6% of diabetes mellitus cases are T1D in the United States (Menke et al., 2013) , so T1D likely constituted only a small proportion of cases of diabetes in our sample. Finally, as noted earlier, medication information was cross-sectional, and thus it was not possible to control for lifetime antipsychotic exposure, or exposure to specific antipsychotics.
Given that individuals with psychosis are at increased risk of T2D, it is important to determine whether genetic markers, including polygenic markers, can help predict emergent metabolic disorders in this high-risk population, particularly in those exposed to antipsychotics. Future investigations could prospectively study associations between glucose dysregulation and genetic risk for T2D while collecting information on longitudinal medication exposure. Models such as homeostatic model assessment (HOMA) (Matthews et al., 1985) and laboratory biomarkers of T2D may be more sensitive correlates of genetic risk, and would be important to measure in future studies. If the predictive value of polygenic risk scores can be further validated, they could eventually help guide clinicians in monitoring and mitigating risk of metabolic disorders and in choosing appropriate pharmacotherapy for patients with psychotic disorders.
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